Updates on cardiovascular outcome trials in diabetes

Cardiovascular Diabetology

Review

Lars Rydén¹  Oliver Schnell²  Eberhard Standl²  Antonio Ceriello³ 

[1] Cardiology Unit, Department of Medicine K2, Karolinska Institute, 171 76, Stockholm, Sweden;Forschergruppe Diabetes e. V., Ingolstaedter Landstraße 1, Neuherberg, 85764, Munich, Germany;Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación, Biomedica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain;Department of Cardiovascular and Metabolic Diseases, IRCCS Multimedica Sesto San Giovanni, Via Milanese 300, 20099, Milan, Italy;

关键词: Cardiovascular risk;    Diabetes;    CVOT;    DEVOTE;    CANVAS program;    EXSCEL;    ACE;    Heart;   

DOI  :  10.1186/s12933-017-0610-y

 received in 2017-09-26, accepted in 2017-10-03,  发布年份 2017

来源: Springer

【 摘 要 】

In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular risk for members of the SGLT-2 and DPP4 inhibitors and GLP-1 receptor agonist classes. The trials confirmed cardiovascular safety for all tested anti-hyperglycaemic drugs and, in addition empagliflozin, semaglutide and liraglutide could even reduce cardiovascular risk. The present review summarizes the results of the DEVOTE, CANVAS, EXSCEL and ACE trials that tested cardiovascular safety of Insulin degludec, canagliflozin, once-weekly exenatide and acarbose and were published in 2017. We provide context on these results by comparing them with earlier trials of glucose-lowering drugs and give an outlook on what to expect in coming years.

【 授权许可】

CC BY   
© The Author(s) 2017